| Literature DB >> 33357644 |
Prakash Chand Negi1, Arvind Kandoria2, Sanjeev Asotra2, Neeraj Kumar Ganju2, Rajeev Merwaha2, Rajesh Sharma2, Kunal Mahajan2, Shivani Rao2.
Abstract
OBJECTIVES: We report the gender-based differences in the prevalence, severity, pattern of valvular involvement, and complications in patients with Rheumatic Fever/Rheumatic heart disease (RF/RHD).Entities:
Keywords: Adverse cardiovascular events; Epidemiology; Gender; Prevalence; Rheumatic fever; Rheumatic heart diseases
Mesh:
Year: 2020 PMID: 33357644 PMCID: PMC7772586 DOI: 10.1016/j.ihj.2020.09.011
Source DB: PubMed Journal: Indian Heart J ISSN: 0019-4832
Gender based differences in the clinical characteristics of the study population.
| Characteristics | Overall study population = 2475 Number (%) | Male 708 (28.6%) Number (%) | Female 1767 (71.4%) Number (%) | p value |
| <10 years | 14 (0.57) | 8 (1.13) | 6 (0.34) | 0.0001 (trends) |
| 11–20 years | 197 (7.9) | 86 (12.1) | 111 (6.3) | |
| 21–29 years | 363 (14.7) | 94 (13.3) | 269 (15.2) | |
| 30–39 years | 582 (23.5) | 165 (23.3) | 417 (23.6) | |
| 40–49 years | 638 (25.8) | 190 (26.8) | 448 (25.3) | |
| 50–59 years | 492 (19.9) | 122 (17.2) | 370 (20.9) | |
| 60–69 years | 140 (5.7) | 33 (4.7) | 107 (6.1) | |
| >70 years | 49 (2.0) | 10 (1.4) | 39 (2.2) | |
| Age, in years (mean ± SD) | 40.6 ± 14.3 | 38.9 ± 14.3 | 41.3 ± 14.1 | 0.0001 |
| Education status below Primary | 1018 (41.1) | 185 (26.1) | 833 (47.1) | 0.0001 |
| Rural background | 2346 (94.8) | 677 (95.6) | 1669 (94.5) | 0.23 |
| Unemployed | 95 (3.8) | 24 (3.4) | 79 (4.2) | 0.001 (trends) |
| Students | 186 (7.5) | 85 (12.0) | 101 (5.7) | |
| Retired | 16 (0.65) | 10 (1.4) | 6 (0.34) | |
| Farming | 966 (36.0) | 417 (58.9) | 549 (31.1) | |
| Employed | 275 (11.1) | 164 (23.2) | 111 (6.3) | |
| House keeping | 937 (37.7) | 8 (1.1) | 929 (52.6) | |
| Male | Female | Odds ratio (95% C.I.) | ||
| Acute rheumatic Fever | 6 (0.85) | 7 (0.40) | 2.1 (0.72–6.4 | 0.31 |
| NYHA class III/IV | 106 (14.9) | 272 (15.4) | 0.96 (0.75–1.23) | 0.76 |
| Atrial fibrillation | 184 (26.1) | 500 (28.3) | 0.88 (0.73–1.08) | 0.52 |
| History of stroke and/or peripheral embolism | 33 (4.6) | 105 (5.9) | 0.75 (0.50–1.13) | 0.20 |
| History of Infective endocarditis | 2 (0.28) | 1 (0.06) | 5.0 (0.91–27.4) | 0.06 |
| High-risk for thromboembolism | 216 (30.5) | 655 (37.1) | 0.86 (0.72–1.04) | 0.12 |
| High-risk population on oral anticoagulation | 127 (58.5) | 383 (58.7) | 0.92 (0.75–1.13) | 0.81 |
| LV systolic dysfunction (LVEF ≤54%) (yes) % | 82 (12.5) | 140 (8.7) | 1.5 (1.12–2.0) | 0.003 |
| PAH (TR velocity >3.0 m/s) | 203 (62.5) | 557 (58.6) | 1.15 (0.89–1.49) | 0.27 |
| Mitral valve disease | 446 (76.1) | 1234 (85.5) | 0.55 (0.44–0.61) | 0.0001 |
| Aortic valve disease | 331 (56.4) | 685 (47.5) | 1.36 (1.14–1.62) | 0.001 |
| Tricuspid valve disease | 263 (44.8) | 792 (54.9) | 0.69 (0.58–0.83) | 0.001 |
| Multi valvular disease | 376 (64.4) | 986 (68.3) | 0.84 (0.72–1.01) | 0.06 |
| Severe valvular heart disease | 261 (44.5) | 643 (44.6) | 0.99 (0.82–1.20) | 0.96 |
| Severe mitral valve disease | 201 (34.2) | 526 (36.4) | 0.90 (0.74–1.11) | 0.13 |
| Severe aortic valve disease | 72 (12.3) | 89 (6.2) | 2.12 (1.53–2.94) | 0.001 |
| Severe tricuspid valve disease | 39 (6.6) | 133 (9.7) | 0.70 (0.48–1.01) | 0.59 |
| Mitral stenosis | 278 (47.4) | 888 (56.0) | 0.70 (0.58–0.85) | 0.001 |
| Mitral regurgitation | 355 (60.5) | 988 (68.5) | 0.70 (0.57–0.86) | 0.001 |
| Aortic regurgitation | 321 (54.7) | 661 (45.8) | 1.42 (1.17–1.73) | 0.001 |
| Aortic stenosis | 100 (17.0) | 193 (13.4) | 1.32 (1.02–1.73) | 0.03 |
| Tricuspid stenosis | 4 (1.4) | 21 (2.7) | 0.49 (0.16–1.46) | 0.19 |
| Tricuspid regurgitation | 262 (44.6) | 789 (54.7) | 0.66 (0.55–0.81) | 0.0001 |
| History of prosthetic valve implantation | 66 (9.3) | 126 (7.1) | 1.33 (0.98–1.82) | 0.06 |
| History of balloon valvuloplasty | 56 (7.9) | 201 (11.4) | 0.66 (0.49–0.91) | 0.01 |
| Proportion of high-risk patients on oral anticoagulants | 169 (68.7) | 611 (66.6) | 1.14 (0.83–1.56) | 0.40 |
| Secondary prophylaxis in eligible patients (age <35 years) | 120 (42.8) | 315 (49.5) | 0.76 (0.57–1.01) | 0.06 |
| Digoxin | 118 (16.7) | 324 (18.3) | 0.89 (0.70–1.12) | 0.32 |
| Beta blockers | 362 (51.1) | 999 (56.5) | 0.80 (0.67–0.95) | 0.01 |
| Diuretics | 326 (46.0) | 961 (54.4) | 0.71 (0.60–0.85) | 0.001 |
| MRA | 406 (57.3) | 1052 (59.5) | 0.91 (0.76–1.09) | 0.31 |
| Ace/ARBs | 228 (32.2) | 484 (27.4) | 1.25 (1.04–1.51) | 0.018 |
Abbreviations: Ace inhibitor/ARB; Angiotensin converting enzyme inhibitors/Angiotensin receptor blockers, LV; left ventricle, LVEF; left ventricular ejection fraction, MRA; Mineralocorticoid receptor antagonist, NYHA class; New York Heart association, PAH; pulmonary artery hypertension, TR; tricuspid regurgitation.
Fig. 1Trends of distribution of Mitral regurgitation (MR), mitral stenosis (MS), across the age groups in male and female genders.
Fig. 2Trends of distribution of aortic regurgitation (AR), aortic stenosis (AS), across age groups in male and female genders.